[go: up one dir, main page]

PE20231108A1 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica

Info

Publication number
PE20231108A1
PE20231108A1 PE2023001370A PE2023001370A PE20231108A1 PE 20231108 A1 PE20231108 A1 PE 20231108A1 PE 2023001370 A PE2023001370 A PE 2023001370A PE 2023001370 A PE2023001370 A PE 2023001370A PE 20231108 A1 PE20231108 A1 PE 20231108A1
Authority
PE
Peru
Prior art keywords
cystic fibrosis
modulators
transmembrane conductance
regulator
methyl
Prior art date
Application number
PE2023001370A
Other languages
English (en)
Inventor
Jason Mccartney
Alexander Russell Abela
Sunny Abraham
Corey Don Anderson
Vijayalaksmi Arumugam
Jaclyn Chau
Jeremy Clemens
Thomas Cleveland
Timothy Richard Coon
Timothy A Dwight
Lev Tyler Dewey Fanning
Brian A Frieman
Peter Grootenhuis
Anton V Gulevich
Ruah Sara Sabina Hadida
Yoshihiro Ishihara
Haripada Khatuya
Paul Krenitsky
Vito Melillo
Mark Thomas Miller
Prasuna Paraselli
Fabrice Pierre
Alina Silina
Joe A Tran
Johnny Uy
Lino Valdez
Troy Vickers
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of PE20231108A1 publication Critical patent/PE20231108A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS MACROCICLICOS DE FORMULA (I) DONDE LOS ANILLOS A Y B, R3, R4, R5, W1, W2, L1, L2, Z Y RYN SON TAL COMO SE DESCRIBEN EN EL PRESENTE DOCUMENTO. SON COMPUESTOS PREFERIDOS: (11R)-11-(CICLOPENTILMETIL)-6-(2,6-DIMETILFENIL)-12-[(6-ISOPROPIL-5-METIL-PIRROLO[2,3-B]PIRAZIN-3-IL)METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; 11-(3,3-DIMETILCICLOBUTIL)-6-(2,6-DIMETILFENIL)-12-[[6-[(2R)-2-METILPIRROLIDIN-1-IL]PIRAZIN-2-IL]METIL]-2,2-DIOXO-9-OXA-2 lamda 6-TIA-3,5,12,19-TETRAZATRICICLO[12.3.1.14,8]NONADECA-1(18),4(19),5,7,14,16-HEXAEN-13-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL REGULADOR DE LA CONDUCTANCIA TRANSMEMBRANA DE LA FIBROSIS QUISTICA (CFTR) SIENDO UTILES EN EL TRATAMIENTO DE FIBROSIS QUISTICA.
PE2023001370A 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica PE20231108A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088686P 2020-10-07 2020-10-07
PCT/US2021/053858 WO2022076622A2 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
PE20231108A1 true PE20231108A1 (es) 2023-07-19

Family

ID=80091350

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001370A PE20231108A1 (es) 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica

Country Status (19)

Country Link
US (1) US20240150377A1 (es)
EP (1) EP4225765A2 (es)
JP (1) JP2023545080A (es)
KR (1) KR20230107725A (es)
CN (1) CN116601158A (es)
AR (1) AR123708A1 (es)
AU (1) AU2021358512A1 (es)
CA (1) CA3197683A1 (es)
CL (1) CL2023000988A1 (es)
CO (1) CO2023005006A2 (es)
CR (1) CR20230198A (es)
DO (1) DOP2023000067A (es)
EC (2) ECSP23033092A (es)
IL (1) IL301757A (es)
MX (1) MX2023004072A (es)
PE (1) PE20231108A1 (es)
TW (1) TW202229298A (es)
UY (1) UY39457A (es)
WO (1) WO2022076622A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544383A (ja) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Cftrモジュレータの結晶形態
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Methods of treatment for cystic fibrosis
EP4472635A1 (en) 2022-02-03 2024-12-11 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2023215372A1 (en) 2022-02-03 2024-08-22 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
CR20240457A (es) * 2022-04-06 2024-12-11 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
JP2025517322A (ja) 2022-05-16 2025-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の治療方法
WO2024054845A1 (en) * 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
IL319374A (en) * 2022-09-07 2025-05-01 Sionna Therapeutics Inc Macrocyclic compounds, compositions and methods of using them
WO2024056779A1 (en) * 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
CN116143722B (zh) * 2023-03-09 2024-05-31 南京师范大学 一种次磺酰胺类化合物的合成工艺
WO2025076240A1 (en) * 2023-10-04 2025-04-10 Vertex Pharmaceuticals Incorporated Solid forms of modulators of cystic fibrosis transmembrane conductance regulator
WO2025129104A1 (en) * 2023-12-15 2025-06-19 Sionna Therapeutics Inc. Compounds, compositions, and methods of using thereof
CN119191996A (zh) * 2024-11-28 2024-12-27 浙江省质量科学研究院 一种双羟乙基氨基丙基羟乙基油胺的合成方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2489659B1 (en) 2004-06-24 2017-12-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
RS60205B1 (sr) 2005-12-28 2020-06-30 Vertex Pharma Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
ES2611077T3 (es) 2007-12-07 2017-05-04 Vertex Pharmaceuticals Incorporated Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico
JP5575768B2 (ja) 2008-08-13 2014-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド 薬学的組成物およびその投与
KR20110063578A (ko) 2008-09-29 2011-06-10 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 투여 단위
KR101587389B1 (ko) 2008-11-06 2016-01-28 버텍스 파마슈티칼스 인코포레이티드 Atp-결합 카세트 수송자의 조절자
PT2408750E (pt) 2009-03-20 2015-10-15 Vertex Pharma Processo para a produção de modeladores do regulador de condutância transmembranar da fibrose cística
DK2826776T3 (da) 2010-03-25 2020-12-14 Vertex Pharma Fast dispersion af amorf form af (r)-1(2,2-difluorbenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluor-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)-cyclopropancarboxamid
EP2556009B1 (en) 2010-04-09 2016-02-10 Ekso Bionics Exoskeleton load handling system and method of use
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
BR112013004130A2 (pt) 2010-08-27 2016-07-05 Vertex Pharma composição farmacêutica e administrações da mesma
SMT201700302T1 (it) 2011-05-18 2017-07-18 Concert Pharmaceuticals Inc Derivati deuterati di ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6302923B2 (ja) 2012-11-02 2018-03-28 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Cftrが媒介する疾患の処置のための医薬組成物
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
PL3131582T3 (pl) 2014-04-15 2018-10-31 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
UA125245C2 (uk) * 2014-10-06 2022-02-09 Вертекс Фармасьютикалз Інкорпорейтед Модулятори регулятора трансмембранної провідності при муковісцидозі
UA124619C2 (uk) 2015-09-21 2021-10-20 Вертекс Фармасьютікалз (Юроп) Лімітед Введення дейтерованих підсилювачів cftr
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
WO2019156946A2 (en) * 2018-02-06 2019-08-15 Research Institute At Nationwide Children's Hospital Compositions and methods for improving cftr function in cystic fibrosis-affected cells
MX2020008268A (es) * 2018-02-15 2020-09-21 Vertex Pharma Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos.
US20220071971A1 (en) * 2018-12-21 2022-03-10 Novartis Ag Macrocyclic compounds and their use in the treatment of disease
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL301755A (en) * 2020-10-07 2023-05-01 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator

Also Published As

Publication number Publication date
EP4225765A2 (en) 2023-08-16
CO2023005006A2 (es) 2023-09-08
CL2023000988A1 (es) 2023-09-15
ECSP23033092A (es) 2023-06-30
CA3197683A1 (en) 2022-04-14
AU2021358512A9 (en) 2024-10-24
TW202229298A (zh) 2022-08-01
MX2023004072A (es) 2023-07-05
CN116601158A (zh) 2023-08-15
ECSP23032843A (es) 2023-06-30
AU2021358512A1 (en) 2023-05-18
UY39457A (es) 2022-05-31
CR20230198A (es) 2023-07-03
KR20230107725A (ko) 2023-07-17
JP2023545080A (ja) 2023-10-26
WO2022076622A2 (en) 2022-04-14
AU2021358512A8 (en) 2023-05-25
IL301757A (en) 2023-05-01
AR123708A1 (es) 2023-01-04
WO2022076622A3 (en) 2022-07-21
US20240150377A1 (en) 2024-05-09
DOP2023000067A (es) 2023-07-09

Similar Documents

Publication Publication Date Title
PE20231108A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
PE20231951A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
PE20231185A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica
PE20210855A1 (es) Peptidos macrociclicos contra actinetobacter baumannii
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
PE20071137A1 (es) Derivados de 8-piracin-s-espiropirimidintriona oxaquinolina como agentes antibacterianos
PE20010130A1 (es) Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
PE20180688A1 (es) Compuestos di-nucleotidos ciclicos como agonistas de sting
PE20230309A1 (es) Agentes quimioterapeuticos de eteres macrociclicos heteroaromaticos
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
AR118497A2 (es) Combinaciones de compuestos activos que comprenden derivados de carboxamida y un agente de control biológico
PE20201185A1 (es) Inhibidores de la oxacina monoacilglicerol lipasa (magl)
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2017008086A2 (es) Dímeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus métodos de preparación y uso
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
PE20170528A1 (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
PE20090247A1 (es) Compuestos amino-heterociclicos
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
PE20090511A1 (es) Imidazopiridinonas
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
GT200900328A (es) Derivados de bencimidazol
CU20210003A7 (es) Una preparación farmacéutica liposomal de mitoxantrona útil en el tratamiento de linfoma no de hodgkin
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.